Hazel Squires

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3724965/publications.pdf

Version: 2024-02-01

430874 454955 40 926 18 30 citations h-index g-index papers 41 41 41 1621 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technology Assessment, 2010, 14, 1-206.	2.8	171
2	Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. British Journal of Surgery, 2012, 99, 1630-1638.	0.3	94
3	Antioxidants in the chemoprevention of colorectal cancer and colorectal adenomas in the general population: a systematic review and meta-analysis. Colorectal Disease, 2011, 13, 1085-1099.	1.4	51
4	A Framework for Developing the Structure of Public Health Economic Models. Value in Health, 2016, 19, 588-601.	0.3	51
5	Routine Antenatal Anti-D Prophylaxis in Women Who Are Rh(D) Negative: Meta-Analyses Adjusted for Differences in Study Design and Quality. PLoS ONE, 2012, 7, e30711.	2.5	49
6	A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease Health Technology Assessment, 2011, 15, 1-210.	2.8	48
7	Whole Disease Modeling to Inform Resource Allocation Decisions in Cancer: A Methodological Framework. Value in Health, 2012, 15, 1127-1136.	0.3	43
8	Costâ€effectiveness of populationâ€based, community, workplace and individual policies for diabetes prevention in the <scp>UK</scp> . Diabetic Medicine, 2017, 34, 1136-1144.	2.3	30
9	The impact of Type 2 diabetes prevention programmes based on riskâ€identification and lifestyle intervention intensity strategies: a costâ€effectiveness analysis. Diabetic Medicine, 2017, 34, 632-640.	2.3	29
10	A systematic literature review of the key challenges for developing the structure of public health economic models. International Journal of Public Health, 2016, 61, 289-298.	2.3	26
11	A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. Health Technology Assessment, 2017, 21, 1-170.	2.8	26
12	Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2016, 34, 673-680.	3.3	25
13	Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation. BMJ Open, 2017, 7, e014953.	1.9	25
14	Views of contraceptive service delivery to young people in the UK: a systematic review and thematic synthesis. Journal of Family Planning and Reproductive Health Care, 2011, 37, 71-84.	0.8	24
15	Development of a Transparent Interactive Decision Interrogator to Facilitate the Decision-Making Process in Health Care. Value in Health, 2011, 14, 768-776.	0.3	22
16	Views regarding the use of contraception amongst young people in the UK: A systematic review and thematic synthesis. European Journal of Contraception and Reproductive Health Care, 2011, 16, 149-160.	1.5	21
17	Cost-effectiveness of interventions to return employees to work following long-term sickness absence due to musculoskeletal disorders. Journal of Public Health, 2012, 34, 115-124.	1.8	21
18	Using Whole Disease Modeling to Inform Resource Allocation Decisions: Economic Evaluation of a Clinical Guideline for Colorectal Cancer Using a Single Model. Value in Health, 2013, 16, 542-553.	0.3	20

#	Article	IF	Citations
19	Systematic review and narrative synthesis of the effectiveness of contraceptive service interventions for young people, delivered in health care settings. Health Education Research, 2012, 27, 1102-1119.	1.9	19
20	Cost-Effectiveness of Cilostazol, Naftidrofuryl Oxalate, and Pentoxifylline for the Treatment of Intermittent Claudication in People With Peripheral Arterial Disease. Angiology, 2014, 65, 190-197.	1.8	18
21	Modelling the Economics of Type 2 Diabetes Mellitus Prevention: A Literature Review of Methods. Applied Health Economics and Health Policy, 2014, 12, 239-253.	2.1	17
22	A statistical model to describe longitudinal and correlated metabolic risk factors: the Whitehall II prospective study. Journal of Public Health, 2016, 38, 679-687.	1.8	16
23	Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 29-38.	3.3	12
24	Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 1073-1080.	3.3	8
25	Cost-Effectiveness of Aspirin, Celecoxib, and Calcium Chemoprevention for Colorectal Cancer. Clinical Therapeutics, 2011, 33, 1289-1305.	2.5	7
26	Methods for handling uncertainty within pharmaceutical funding decisions. International Journal of Systems Science, 2014, 45, 60-68.	5.5	6
27	Conceptualising changes to tobacco and alcohol policy as affecting a single interlinked system. BMC Public Health, 2021, 21, 17.	2.9	6
28	Qualitative research to inform economic modelling: a case study in older people's views on implementing the NICE falls prevention guideline. BMC Health Services Research, 2021, 21, 1020.	2.2	6
29	A cost-effectiveness analysis of condom distribution programmes for the prevention of sexually transmitted infections in England. Journal of Epidemiology and Community Health, 2017, 71, 897-904.	3.7	5
30	Adalimumab for non-infectious uveitis: is it cost-effective?. British Journal of Ophthalmology, 2019, 103, 1633-1638.	3.9	5
31	Economic models of community-based falls prevention: a systematic review with subsequent commissioning and methodological recommendations. BMC Health Services Research, 2022, 22, 316.	2.2	5
32	Dexamethasone implant for non-infectious uveitis: is it cost-effective?. British Journal of Ophthalmology, 2019, 103, 1639-1644.	3.9	4
33	The price of precision: trade-offs between usability and validity in the World Health Organization Health Economic Assessment Tool for walking and cycling. Public Health, 2021, 194, 263-269.	2.9	4
34	Economic evaluation of community-based falls prevention interventions for older populations: a systematic methodological overview of systematic reviews. BMC Health Services Research, 2022, 22, 401.	2.2	4
35	Systematic review and critical methodological appraisal of community-based falls prevention economic models. Cost Effectiveness and Resource Allocation, 2022, 20, .	1.5	3
36	PCN193 Using Whole Disease Modelling to Inform Economic Recommendations for the Detection, Diagnosis, Treatment and Follow-up of Colorectal Cancer. Value in Health, 2011, 14, A469-A470.	0.3	2

#	Article	IF	CITATIONS
37	Authors' reply: Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630–1638). British Journal of Surgery, 2013, 100, 1838-1839.	0.3	2
38	OP131 Cost-Effectiveness Of Dexamethasone And Adalimumab For Uveitis. International Journal of Technology Assessment in Health Care, 2017, 33, 60-61.	0.5	1
39	A comparison of the World Health Organisation's HEAT model results using a non-linear physical activity dose response function with results from the existing tool. Wellcome Open Research, 0, 7, 7.	1.8	O
40	A comparison of the World Health Organisation's HEAT model results using a non-linear physical activity dose response function with results from the existing tool. Wellcome Open Research, 0, 7, 7.	1.8	0